Measuring the impact of chemotherapy on fertility in women with breast cancer [11]

Journal of Clinical Oncology

Volumn 24, Issue 24, 2006, Pages 4044-4046

  Oktay, Kutluk ^a   Oktem, Ozgur ^a   Reh, Andrea ^b   Vahdat, Linda ^b  

^a Department of Obstetrics Gynecology   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTRADIOL; FLUOROURACIL; FOLLITROPIN; INHIBIN B; MUELLERIAN INHIBITING FACTOR; PACLITAXEL; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; GLYCOPROTEIN; MULLERIAN INHIBITING HORMONE; MULLERIAN-INHIBITING HORMONE; TESTIS PEPTIDE HORMONE;

AGING; AMENORRHEA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVOR; FERTILITY; FOLLOW UP; HUMAN; INFERTILITY; LETTER; MENSTRUAL CYCLE; OVARY INSUFFICIENCY; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SIDE EFFECT; ADULT; BLOOD; BREAST TUMOR; DRUG EFFECT; FEMALE; MENSTRUATION; MIDDLE AGED; NOTE; OVARY FOLLICLE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; ESTRADIOL; FEMALE; FERTILITY; FOLLICLE STIMULATING HORMONE; GLYCOPROTEINS; HUMANS; MENSTRUATION; MIDDLE AGED; OVARIAN FOLLICLE; TESTICULAR HORMONES;

EID: 33748456740     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.06.9823     Document Type: Letter

References (24)

1. Petrek JA, Naughton MJ, Case LD, et al: Incidence, time course, and determinants of menstrual bleeding after breast cancer treatment: A prospective study. J Clin Oncol 24:1045-1051, 2006
2. te Velde ER, Pearson PL: The variability of female reproductive aging. Hum Reprod Update 8:141-154, 2002
3. Licciardi FL, Liu HC, Rosenwaks Z: Day 3 estradiol serum concentrations as prognosticators of ovarian stimulation response and pregnancy outcome in patients undergoing in vitro fertilization. Fertil Steril 64:991-994, 1995
4. Lutchman Singh K, Davies M, Chatterjee R: Fertility in female cancer survivors: Pathophysiology, preservation and the role of ovarian reserve testing. Hum Reprod Update 11:69-89, 2005
5. Klein NA, Battaglia DE, Fujimoto VY, et al: Reproductive aging: Accelerated ovarian follicular development associated with a monotropic follicle-stimulating hormone rise in normal older women. J Clin Endocrinol Metab 81:1038-1045, 1996
6. Baarends WM, Uilenbroek JT, Kramer P, et al: Anti-Mullerian hormone and anti-Mullerian hormone type II receptor messenger ribonucleic acid expression in rat ovaries during postnatal development, the estrous cycle, and gonadotropin-induced follicle growth. Endocrinology 136:4951-4962, 1995
7. Durlinger AL, Visser JA, Themmen AP: Regulation of ovarian function: The role of anti-Mullerian hormone. Reproduction 124:601-609, 2002
8. van Rooij IA, Broekmans FJ, te Velde ER, et al: Serum anti-Mullerian hormone levels: A novel measure of ovarian reserve. Hum Reprod 17:3065-3071, 2002
9. Fanchin R, Schonauer LM, Righini C, et al: Serum anti-Mullerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod 18:323-327, 2003
10. Gougeon A: Regulation of ovarian follicular development in primates: Facts and hypotheses. Endocr Rev 17:121-155, 1996
11. Faddy MJ, Gosden RG: A model conforming the decline in follicle numbers to the age of menopause in women. Hum Reprod 11:1484-1486, 1996
12. Scheffer GJ, Broekmans FJ, Bancsi LF, et al: Quantitative transvaginal two-and three-dimensional sonography of the ovaries: Reproducibility of antral follicle counts. Ultrasound Obstet Gynecol. 20:270-275, 2002
13. Scheffer GJ, Broekmans FJ, Looman CW, et al: The number of antral follicles in normal women with proven fertility is the best reflection of reproductive age. Hum Reprod 18:700-706, 2003
14. Broekmans FJ, Faddy MJ, Scheffer G, et al: Antral follicle counts are related to age at natural fertility loss and age at menopause. Menopause 11:607-614, 2004
15. Larsen EC, Muller J, Schmiegelow K, et al: Reduced ovarian function in long-term survivors of radiation- and chemotherapy-treated childhood cancer. J. Clin Endocrinol Metab. 88:5307-5314, 2003
16. Larsen EC, Muller J, Rechnitzer C, et al: Diminished ovarian reserve in female childhood cancer survivors with regular menstrual cycles and basal FSH <10 IU/l. Hum. Reprod 18:417-1422, 2003
17. Bath LE, Wallace WH, Shaw MP, et al: Depletion of ovarian reserve in young women after treatment for cancer in childhood: Detection by anti-Mullerian hormone, inhibin B and ovarian ultrasound. Hum Reprod 18:2368-2374, 2003
18. Oktay K, Buyuk E, Libertella N, et al: Fertility preservation in breast cancer patients: A prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation. J Clin Oncol 23:4347-4353, 2005
19. Klijn JGM, Beex LV, Mauriac L, et al: Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: A randomized study. J Natl Cancer Inst 92:903-911, 2000
20. Cook CL, Siow Y, Taylor S, et al: Serum mullerian-inhibiting substance levels during normal menstrual cycles. Fertil Steril 73:859-861, 2000
21. Meirow D, Nugent D: The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update 7:535-543, 2001
22. Sonmezer M, Oktay K: Fertility preservation in female patients. Hum Reprod Update 10:251-266, 2004
23. Byrne J, Fears TR, Gail MH, et al: Early menopause in long-term survivors of cancer during adolescence. Am J Obstet Gynecol 166:788-793, 1992
24. Lee SJ, Schover LR, Partridge AH, et al: American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 24:2917-2931, 2006